Head-To-Head Survey: Sanara MedTech (NASDAQ:SMTI) vs. ReWalk Robotics (NASDAQ:LFWD)

Sanara MedTech (NASDAQ:SMTI) and ReWalk Robotics (NASDAQ:LFWD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

Sanara MedTech has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Institutional and Insider Ownership

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 26.8% of ReWalk Robotics shares are owned by institutional investors. 54.1% of Sanara MedTech shares are owned by insiders. Comparatively, 2.5% of ReWalk Robotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sanara MedTech and ReWalk Robotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-10.71%	-19.86%	-10.91%
ReWalk Robotics	-77.21%	-43.02%	-31.53%

Earnings and Valuation

This table compares Sanara MedTech and ReWalk Robotics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$64.99 million	5.06	-$4.30 million	($0.99)	-38.01
ReWalk Robotics	$13.85 million	0.94	-$22.13 million	($2.49)	-0.59

Sanara MedTech has higher revenue and earnings than ReWalk Robotics. Sanara MedTech is trading at a lower price-to-earnings ratio than ReWalk Robotics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Sanara MedTech and ReWalk Robotics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	0	0	2	0	3.00
ReWalk Robotics	0	0	1	1	3.50

Sanara MedTech currently has a consensus price target of $47.00, indicating a potential upside of 24.90%. ReWalk Robotics has a consensus price target of $13.00, indicating a potential upside of 778.38%. Given ReWalk Robotics’ stronger consensus rating and higher probable upside, analysts clearly believe ReWalk Robotics is more favorable than Sanara MedTech.

Summary

Sanara MedTech beats ReWalk Robotics on 9 of the 15 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.